Overall survival results from a phase III trial of trifluridine/tipiracil versus placebo in patients with metastatic gastric cancer refractory to standard therapies (TAGS).
Authors
Tabernero, JShitara, K
Dvorkin, M
Mansoor, Was
Arkenau, H
Prokharau, A
Alsina, M
Ghidini, M
Faustino, C
Gorbunova, V
Zhavrid, E
Nishikawa, K
Hosokawa, A
Ganea, D
Yalçın, Ş
Fujitani, K
Beretta, G
Winkler, R
Makris, L
Doi, T
Ilson, D
Affiliation
Vall d’Hebron University Hospital and Vall d’Hebron Institute of Oncology, Barcelona, SpainIssue Date
2018-06
Metadata
Show full item recordCitation
Overall survival results from a phase III trial of trifluridine/tipiracil versus placebo in patients with metastatic gastric cancer refractory to standard therapies (TAGS). 2018, 29(suppl_5): Ann OncolJournal
Annals of OncologyDOI
10.1093/annonc/mdy208.001Type
Meetings and ProceedingsLanguage
enISSN
0923-75341569-8041
ae974a485f413a2113503eed53cd6c53
10.1093/annonc/mdy208.001